CD46 Antibody

What is CD46 and why is it a significant research target?

CD46, also known as Membrane Cofactor Protein (MCP) or MIC10, is a ubiquitously expressed type-I transmembrane glycoprotein that functions as a cofactor for complement factor I to mediate inactivation of complement components. Its significance stems from its multifunctional role in complement inhibition, which may explain its overexpression in malignant cells . CD46 is also involved in pathogen entry, including measles virus, making it relevant to both immunology and oncology research . The protein has a calculated molecular weight of 43 kDa, though it typically appears at 50-70 kDa in experimental conditions due to post-translational modifications .

What are the common applications for CD46 antibodies in laboratory research?

CD46 antibodies have been validated for multiple laboratory applications, with specific optimal dilutions for each technique:

These applications allow researchers to detect CD46 expression in various cell lines including A549, HeLa, Jurkat, and MOLT-4 cells . For optimal results, experimental conditions should be titrated for each specific research system as sensitivity may vary between applications and sample types .

How should CD46 antibodies be stored and handled to maintain reactivity?

CD46 antibodies are typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . For optimal preservation of antibody function, store at -20°C where they remain stable for one year after shipment. Unlike some antibodies, those stored in this buffer don't require aliquoting for -20°C storage, reducing handling time and potential contamination. Some formulations (20μl sizes) contain 0.1% BSA as a stabilizer . When working with these antibodies, minimize freeze-thaw cycles and keep on ice during experiments to maintain binding efficacy.

What are the optimal antigen retrieval methods for CD46 immunohistochemistry?

For successful CD46 detection in tissue samples, antigen retrieval methodology significantly impacts staining quality. The recommended primary approach is using TE buffer at pH 9.0 . This alkaline pH is particularly effective for exposing CD46 epitopes in formalin-fixed, paraffin-embedded tissues. As an alternative when this method yields suboptimal results, citrate buffer at pH 6.0 can be employed . CD46 antibodies have been successfully validated for IHC in multiple human cancer tissues, including ovary, breast, colon, and cervical cancer samples . When developing new IHC protocols, researchers should include appropriate positive controls (such as human colon cancer tissue) and optimize antibody concentration within the recommended 1:50-1:500 dilution range .

How can researchers effectively validate CD46 antibody specificity in their experimental systems?

Validating antibody specificity is crucial for reliable experimental outcomes. For CD46 antibodies, a multi-faceted validation approach is recommended:

• Competitive binding assays: Perform binding inhibition with recombinant CD46-Fc fusion proteins. Researchers have successfully demonstrated competitive inhibition using increasing concentrations of CD46-Fc fusion protein to block antibody binding .

• Genetic knockdown validation: Use shRNA against CD46 to reduce target expression. Previous research has achieved approximately 82% knockdown of CD46 antigen density (from 146,647 to 25,847 molecules per cell) in GFP-positive cells following lentiviral shRNA delivery . This approach allows for direct correlation between target expression and antibody binding.

• Western blot analysis: Confirm expected molecular weight patterns (50-70 kDa observed vs. 43 kDa calculated) and compare against both positive and negative control cell lines .

• Cross-reactivity testing: While some CD46 antibodies show reactivity with both human and mouse samples, others are human-specific. Verify species reactivity experimentally before planning cross-species studies .

How can CD46 antibodies be utilized in antibody-drug conjugate (ADC) development for cancer therapy?

CD46 antibodies have demonstrated significant potential in ADC development, particularly for multiple myeloma treatment. When developing CD46-targeting ADCs, consider the following research-validated approaches:

• Internalization assays: Confirm antibody internalization via confocal microscopy, focusing on colocalization with lysosomal markers such as LAMP1. CD46 antibodies with demonstrated internalization via macropinocytosis (a tumor-selective pathway) have proven particularly effective for ADC development .

• Linker-payload optimization: The valine-citrulline linker coupled with monomethyl auristatin F (MMAF) has shown efficacy in CD46-ADC development, achieving drug-to-antibody ratios of approximately 3.3 . This can be verified using hydrophobic interaction chromatography.

• Potency assessment: Successful CD46-ADCs have demonstrated EC50 values in the picomolar range (150 pM to 5 nM) against multiple myeloma cell lines, with minimal effect on normal cells even at concentrations exceeding 100 nM .

• Target expression correlation: Surface expression levels of CD46, quantified by flow cytometry, inversely correlate with the EC50 of CD46-ADC, suggesting that surface expression levels can serve as a reasonable surrogate for potency prediction .

What considerations apply when studying CD46 expression in the context of genomic alterations?

The CD46 gene resides on chromosome 1q, which undergoes genomic amplification in a majority of relapsed myeloma patients, making it an important research consideration in oncology studies . When investigating CD46 in the context of genomic alterations:

• Quantitative expression analysis: Cell surface expression of CD46 is markedly higher in patient myeloma cells with 1q gain compared to those with normal 1q copy number. Flow cytometry can quantify this difference, with multiple myeloma cell lines showing CD46 antigen densities of 454,668-470,991 molecules per cell, compared to 314,953-344,865 for CD38 (another common myeloma marker) .

• Chromosome 1q analysis: Include fluorescence in situ hybridization (FISH) analysis for chromosome 1q21 amplification when studying CD46 in cancer samples, as this genomic alteration may serve as a surrogate for CD46 target amplification .

• Transcriptomic correlation: CD46 transcript levels correlate with cell surface expression and inversely correlate with ADC EC50 values, suggesting that both genomic and transcriptomic analyses provide valuable insights into potential therapeutic response .

How does the bone marrow microenvironment affect CD46 expression and therapeutic targeting?

Research has revealed important interactions between CD46 expression and the bone marrow microenvironment that should be considered in experimental design:

• Co-culture systems: When developing in vitro models, consider that CD46 expression levels can be upregulated upon co-culture with bone marrow stromal cells, potentially affecting therapeutic targeting and antibody binding affinity .

• Stromal protection assessment: While many therapeutic targets show reduced drug sensitivity in the presence of bone marrow stroma, CD46-targeted approaches may be potentiated in models of the bone marrow microenvironment, an important consideration for therapeutic development .

• Orthometastatic models: For in vivo studies, orthometastatic xenograft models using luciferase-expressing cells (e.g., RPMI8226-Luc) provide more physiologically relevant systems for studying CD46-targeted therapeutics than simple subcutaneous models .

What strategies can address variable molecular weight observations for CD46 in Western blot applications?

Researchers frequently observe CD46 at molecular weights of 50-70 kDa despite its calculated weight of 43 kDa . This discrepancy results from:

• Post-translational modifications: CD46 undergoes extensive glycosylation that increases its apparent molecular weight.

• Alternative splicing: Multiple CD46 isoforms exist, contributing to size variation.

To address this variability:

• Include positive control lysates from validated cells (A549, HeLa, Jurkat, MOLT-4) with known CD46 expression patterns .

• Optimize sample preparation by using protease and phosphatase inhibitors.

• Consider using gradient gels (4-15%) to better resolve the range of potential molecular weights.

• Validate observations with multiple antibody clones targeting different CD46 epitopes to confirm specificity of bands.

How can researchers assess and account for CD46 shedding in experimental systems?

CD46 antigen shedding from the cell surface has been reported in solid tumor cell lines and may impact experimental results . To account for this phenomenon:

• Western blot analysis of supernatants: Examine both cell lysates and culture supernatants to detect shed CD46 antigens that might influence antibody binding quantification.

• Flow cytometry standardization: Use quantitative flow cytometry with appropriate calibration beads to determine absolute CD46 antigen density per cell (molecules/cell) rather than relative fluorescence intensity, allowing more accurate comparisons between experiments and cell types .

• Time-course considerations: When designing experiments, account for potential time-dependent changes in surface CD46 levels due to shedding, especially in longer-term culture systems.

What factors influence CD46 antibody affinity and how can binding kinetics be accurately measured?

Understanding antibody-target binding kinetics is crucial for research applications. Published CD46 antibodies have demonstrated high affinity with equilibrium dissociation constants (KD) ranging from 1.19-2.99 nM . To accurately measure and optimize binding:

• Surface plasmon resonance: Use systems like BLItz to determine KD values on recombinant CD46 protein fragments for initial characterization .

• Cell-based binding assays: Measure binding kinetics on living cells to account for the native conformation and microenvironment of CD46. Previous studies have shown KD values of 1.19 nM for RPMI8226 cells and 2.24 nM for MM1.S cells .

• Competition assays: Evaluate binding specificity through displacement assays using recombinant CD46 proteins or peptides corresponding to specific domains of CD46 .

• Buffer optimization: Consider that binding affinity may be influenced by buffer conditions, calcium concentration, and the presence of other complement components in the experimental system.

How does CD46 research integrate with emerging immunotherapy approaches?

CD46's role in complement regulation and pathogen entry positions it at the intersection of multiple immunotherapy strategies. Researchers investigating CD46 antibodies should consider:

• Complement-dependent cytotoxicity: While CD46 normally protects cells from complement-mediated lysis, certain antibody formats or combinations might overcome this protection.

• Viral immunotherapy integration: CD46 serves as an entry receptor for measles virus, suggesting potential combination approaches between CD46-targeted antibodies and viral immunotherapy using the Edmonston strain of measles virus .

• Dual-function antibodies: Designing antibodies that both block CD46's complement regulatory function and deliver cytotoxic payloads may provide synergistic therapeutic effects.